• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP

    2/26/24 9:03:59 AM ET
    $NGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NGM alert in real time by email
    • NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transaction
    • Based on a thorough exploration and review of strategic and financial alternatives, a Special Committee of independent and disinterested directors unanimously recommends the transaction

    SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ("NGM Bio") (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") under which Atlas Neon Parent, Inc. ("Purchaser") and Atlas Neon Merger Sub, Inc. ("Merger Sub") will acquire NGM Bio through a cash tender offer to be commenced by Merger Sub for all outstanding shares of NGM Bio not held by affiliates of The Column Group, LP and certain other stockholders, as described below, at a price per share of $1.55 in cash. Purchaser and Merger Sub are affiliates of The Column Group, LP (together with certain of The Column Group, LP's affiliates, the "TCG Stockholders"), NGM Bio's longest and largest stockholder, holding approximately 26% of NGM Bio's outstanding shares.

    The TCG Stockholders and certain other existing stockholders of NGM Bio (the "Rollover Stockholders") have agreed to contribute their shares of NGM Bio stock to Purchaser as a part of the transaction rather than receive the cash price per share.

    This price per share corresponds to a total equity value of $135 million on a fully diluted basis and represents an 80% premium over the last trading day closing price (December 29, 2023) prior to NGM Bio's Form 8-K confirming receipt from the TCG Stockholders of a non-binding expression of interest in exploring and evaluating a potential acquisition of all of the outstanding shares of common stock of NGM Bio not already owned by the TCG Stockholders in a going-private transaction. NGM Bio's cash, cash equivalents and short-term marketable securities were $166.0 million as of September 30, 2023 and an estimated $144.2 million as of December 31, 2023.

    Following a thorough exploration and review of strategic and financial alternatives with the assistance of its legal and financial advisors, a Special Committee of the NGM Bio Board of Directors (the "Special Committee"), consisting solely of independent and disinterested members of the NGM Bio Board of Directors (the "Board"), determined that the acquisition by Purchaser is in the best interests of NGM Bio stockholders (excluding the TCG Stockholders, Purchaser, Merger Sub, the Rollover Stockholders, the members of the Board and the officers of NGM Bio subject to Section 16 of the Exchange Act, referred to as the "Unaffiliated Stockholders"), and unanimously recommended approval of the Merger Agreement to the Board. The Special Committee and NGM Bio management team explored a range of strategic options, including engaging with multiple potential third party acquirors, before negotiating and entering into the Merger Agreement.

    "We conducted a thorough review of our financial and strategic alternatives, including remaining a publicly held company, with particular focus on NGM Bio's ongoing need for significant additional funding. Based on this review, we believe that this negotiated transaction for Purchaser to acquire NGM Bio is in the best interest of the Unaffiliated Stockholders," said Suzanne Sawochka Hooper, an independent member of the Board and Chair of the Special Committee.

    Based upon the recommendation of the Special Committee, with the assistance of its legal and financial advisors, the Board determined that the acquisition by Purchaser is in the best interests of the Unaffiliated Stockholders, and approved the Merger Agreement.

    Closing of the tender offer is subject to the satisfaction of certain customary conditions, including the tender of NGM Bio shares representing at least a majority of the total number of outstanding shares held by the Unaffiliated Stockholders. The tender offer is not subject to a financing contingency.

    Promptly following the closing of the tender offer, Merger Sub will merge with and into NGM Bio, and all remaining shares not tendered in the offer, other than dissenting shares, treasury shares and rollover shares held by the TCG Stockholders, Purchaser and any other subsidiary of Purchaser, or the Rollover Stockholders, will be converted into the right to receive a price per share of $1.55 in cash. The acquisition is expected to close in the second quarter of 2024. If completed, the transaction will result in NGM Bio becoming a privately held company and its shares will no longer be listed on Nasdaq.

    Advisors

    Guggenheim Securities, LLC is acting as exclusive financial advisor and Hogan Lovells US LLP is acting as legal counsel to the Special Committee. Paul, Weiss, Rifkind, Wharton & Garrison LLP is acting as legal counsel to Purchaser.

    About NGM Biopharmaceuticals, Inc.

    NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. NGM Bio's biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. Visit us at www.ngmbio.com for more information.

    Cautionary Notice Regarding Forward-Looking Statements

    Statements contained in this communication regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes," "estimates," "expects," "focused," "continuing to," "seeking," "will" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to: the ability of NGM Bio and Purchaser to complete the transactions contemplated by the Merger Agreement, including the parties' ability to satisfy the conditions to the consummation of the tender offer contemplated thereby and the other conditions set forth in the Merger Agreement, statements about the expected timetable for completing the transactions, NGM Bio's and Purchaser's beliefs and expectations and statements about the benefits sought to be achieved by Purchaser's proposed acquisition of NGM Bio, the potential effects of the acquisition on both NGM Bio and Purchaser, the possibility of any termination of the Merger Agreement, estimates relating to NGM Bio's past, current or future financial condition and other statements that are not historical fact.

    Because such statements deal with future events and are based on NGM Bio's current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of NGM Bio could differ materially from those described in or implied by the statements in this communication. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with: the timing of the tender offer and the subsequent merger; uncertainties as to how many of the Unaffiliated Stockholders will tender their shares in the tender offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the tender offer and the subsequent merger may not be satisfied or waived; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, including in circumstances which would require NGM Bio to pay a termination fee; the effects of disruption from the transactions contemplated by the Merger Agreement; the risk that stockholder litigation in connection with the tender offer or the merger may result in significant costs of defense, indemnification and liability; and other risks and uncertainties affecting NGM Bio and its development programs, including those discussed in the section titled "Risk Factors" in NGM Bio's Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 28, 2023, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings and reports that NGM Bio makes from time to time with the SEC. Except as required by law, NGM Bio assumes no obligation to update these forward-looking statements, which speak only as of the date they are made, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

    Additional Information and Where to Find It

    The tender offer for the outstanding shares of common stock of NGM Bio referenced in this communication has not yet commenced. This communication is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell shares of common stock of NGM Bio or any other securities. This communication is also not a substitute for the tender offer materials that Purchaser will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Purchaser will file with the SEC a Tender Offer Statement on Schedule TO and a Transaction Statement on Schedule 13E-3 ("Schedule 13E-3"), and NGM Bio will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 and a Schedule 13E-3.

    NGM BIO'S STOCKHOLDERS ARE URGED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION / RECOMMENDATION STATEMENT AND THE SCHEDULES 13E-3 WHEN SUCH DOCUMENTS BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER.

    When filed, NGM Bio's stockholders and other investors can obtain the Tender Offer Statement, the Solicitation/Recommendation Statement, the Schedules 13E-3 and other filed documents for free at the SEC's website at www.sec.gov. Copies of the documents filed with the SEC by NGM Bio will be available free of charge on the Investors & Media page of NGM Bio's website, www.ngmbio.com, or by contacting NGM Bio at [email protected]. In addition, NGM Bio's stockholders may obtain free copies of the tender offer materials by contacting the information agent for the tender offer that will be named in the Tender Offer Statement.

    Availability of Other Information about NGM Biopharmaceuticals

    NGM Bio intends to use the Investors & Media page of its website (https://ir.ngmbio.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor NGM Bio's Investors page on its website, in addition to following NGM Bio's press releases, SEC filings, public conference calls, presentations and webcasts.

    For further information, please contact:

    NGM Biopharmaceuticals, Inc.

    Investor Contact:

    [email protected]

    Media Contact:

    [email protected] 



    Primary Logo

    Get the next $NGM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NGM

    DatePrice TargetRatingAnalyst
    3/12/2024Outperform → Mkt Perform
    Raymond James
    2/28/2024Outperform → Market Perform
    TD Cowen
    2/27/2024Buy → Neutral
    Citigroup
    5/3/2023$6.00Buy
    Citigroup
    10/18/2022$29.00 → $4.00Buy → Neutral
    Goldman
    10/18/2022$42.00 → $4.00Strong Buy → Outperform
    Raymond James
    10/17/2022Buy → Hold
    Jefferies
    10/17/2022Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $NGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NGM Biopharmaceuticals downgraded by Raymond James

      Raymond James downgraded NGM Biopharmaceuticals from Outperform to Mkt Perform

      3/12/24 7:29:29 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Biopharmaceuticals downgraded by TD Cowen

      TD Cowen downgraded NGM Biopharmaceuticals from Outperform to Market Perform

      2/28/24 6:43:03 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Biopharmaceuticals downgraded by Citigroup

      Citigroup downgraded NGM Biopharmaceuticals from Buy to Neutral

      2/27/24 8:54:39 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NGM Bio Announces Closing of Tender Offer

      SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. ("NGM Bio") (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. ("Parent"), an affiliate of The Column Group, LP ("TCG"), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. ("Merger Sub"), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of TCG and certain other stockholders at a price per share of $1.55 in cash (the "Offer Price"). The tender offer and related withdrawal rights expired at one minute a

      4/5/24 9:19:51 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

      SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA. Poster Presentation Details: Title: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose esca

      3/19/24 5:30:44 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

      --Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024-- --Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravidarum (HG) by the end of 2024-- --Ongoing discussions with regulators on the design of a potential registrational trial of aldafermin, an engineered FGF19 analog, for the treatment of primary sclerosing chola

      3/11/24 4:05:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    SEC Filings

    See more
    • SEC Form 15-12G filed by NGM Biopharmaceuticals Inc.

      15-12G - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)

      4/15/24 7:57:22 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by NGM Biopharmaceuticals Inc.

      EFFECT - NGM BIOPHARMACEUTICALS INC (0001426332) (Filer)

      4/9/24 12:15:15 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by NGM Biopharmaceuticals Inc.

      25-NSE - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      4/5/24 11:22:54 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Column Group L P bought $15,507 worth of shares (22,631 units at $0.69) (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      11/17/23 4:33:24 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group L P bought $15,507 worth of shares (22,631 units at $0.69) (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      11/17/23 4:30:19 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group L P bought $15,507 worth of shares (22,631 units at $0.69) (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      11/17/23 4:28:01 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tcg Opportunity Iii Gp, Llc returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      4/8/24 8:05:48 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group Gp, Lp returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      4/8/24 8:04:43 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Column Group L P returned 21,743,413 shares to the company and acquired 1,000 shares (SEC Form 4)

      4 - NGM BIOPHARMACEUTICALS INC (0001426332) (Issuer)

      4/8/24 8:03:30 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Leadership Updates

    Live Leadership Updates

    See more
    • NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data

      Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with 3 mg of aldafermin, an engineered FGF19 analog product candidate, compared to patients treated with placeboInitiated the first two Phase 2b expansion cohorts in the Phase 1/2 trial evaluating NGM707, an ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab)Announced the appointment of Dan Kaplan, Ph.D. to Chief Scientific OfficerExtended expected cash runway into the second quarter of 2025 following a restructuring o

      5/4/23 4:05:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marathon Health Expands Board of Directors

      INDIANAPOLIS, Feb. 8, 2022 /PRNewswire/ -- Marathon Health announces the addition of four members to its Board of Directors, as the company continues to accelerate plans to achieve its mission of fixing the U.S. health system by scaling its advanced primary care model.  Ms. Obi Felton, Ms. Siobhan Nolan Mangini, Dr. Glenn Steele and Mr. Bill Whitely bring a strong and diverse set of track records and experience, spanning leadership in clinical quality, patient experience, technology, and rapid growth. Marathon's appointment of these four Directors comes at an exciting inflecti

      2/8/22 7:00:00 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results

      Completed enrollment in 320-patient Phase 2 CATALINA study of NGM621, an anti-complement C3 antibody, for the treatment of geographic atrophy; topline data expected in second half of 2022Initiated a Phase 1/2 clinical trial of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumorsAmended collaboration with Merck to focus primarily on advancing novel medicines for retinal and cardiovascular and metabolic diseases; NGM gained worldwide rights to its disclosed oncology portfolio as well as additional assets falling outside of the amended collaboration's narrower scope$390.6 million in cash, cash equivalents and marketable securities as of June 30, 2021 SOUTH SAN

      8/5/21 4:05:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Financials

    Live finance-specific insights

    See more
    • NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

      Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus shamNGM621 showed favorable safety and tolerability, with no evidence of increased CNV conversion and no treatment-related SAEsAdditional analyses to be presented in early November at The Retina Society Annual Scientific MeetingNGM Bio to host conference call and webcast today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced topline efficacy

      10/17/22 7:30:00 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

      SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to discuss topline efficacy and safety results from its CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration. To access the live webcast and slides, please visit the "Investors & Media" section of NGM Bio's website at https://ir.ngmbio.com/. The webcast will be archived for 30 days. About NGM Bio NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives ha

      10/16/22 4:30:00 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by NGM Biopharmaceuticals Inc. (Amendment)

      SC 13D/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      4/5/24 10:55:55 AM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by NGM Biopharmaceuticals Inc. (Amendment)

      SC 13D/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      2/26/24 5:16:16 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NGM Biopharmaceuticals Inc. (Amendment)

      SC 13G/A - NGM BIOPHARMACEUTICALS INC (0001426332) (Subject)

      2/14/24 6:12:53 PM ET
      $NGM
      Biotechnology: Pharmaceutical Preparations
      Health Care